Oral Wegovy: The First GLP-1 Weight Loss Pill
FDA-approved December 2025 and available at pharmacies nationwide. Here's what the clinical data actually shows, what it costs, and how it compares to the injectable version you already know.
Oral Wegovy (semaglutide 25 mg tablet) delivers weight loss comparable to the injection — about 16.6% of body weight over 64 weeks in clinical trials. It costs $149/month at starter doses through August 2026, doesn't require refrigeration, and is covered by most commercial insurance plans at $0–$25/month. Medicare coverage begins July 2026.
What Is Oral Wegovy?
Oral Wegovy is a once-daily tablet containing semaglutide, the same active ingredient found in injectable Wegovy and Ozempic. The FDA approved it on December 22, 2025 for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related health condition. It also carries an indication for reducing cardiovascular risk — heart attack, stroke, and cardiovascular death — in these patients.
It's the first and, as of April 2026, only oral GLP-1 medication approved specifically for weight loss. (Rybelsus, also an oral semaglutide product, is approved only for type 2 diabetes at lower doses.)
How the Pill Works: SNAC Technology
Semaglutide is a peptide. For a detailed explanation of how GLP-1 medications work in your body, see our guide to the mechanism of GLP-1 drugs. Like insulin, peptides get destroyed by stomach acid before they can be absorbed — which is why GLP-1 medications were injection-only for years. Oral Wegovy solves this with a co-formulated absorption enhancer called SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate).
SNAC creates a temporary pH buffer in a small area of the stomach lining, protecting the semaglutide molecule long enough for it to cross the stomach wall and enter the bloodstream. A 2025 study in Nature Communications detailed the molecular mechanism behind this transcellular absorption process.
Here's the catch: only about 0.4–1% of the semaglutide in each tablet actually reaches systemic circulation. That's why the oral dose is 25 mg while the injectable dose maxes out at 2.4 mg — the tablet contains far more active ingredient to compensate for low bioavailability. And it's why the fasting requirement matters so much. Food in the stomach interferes with SNAC's protective effect.
- Take the tablet first thing in the morning, on an empty stomach.
- Swallow whole with no more than 4 ounces (120 ml) of plain water.
- Wait at least 30 minutes before eating, drinking anything else, or taking other medications.
- Do not split, crush, or chew the tablet.
Clinical Trial Results
Oral semaglutide for weight loss was studied across the OASIS clinical trial program. Here are the key results:
OASIS 4 (Basis for FDA Approval)
This was the pivotal trial that earned the FDA nod. Published in 2025, it enrolled 307 adults with obesity or overweight plus at least one weight-related condition (but without type 2 diabetes).
- Dose: 25 mg once daily (the approved dose)
- Duration: 64 weeks
- Average weight loss: 16.6% (semaglutide) vs. 2.7% (placebo)
- ≥20% weight loss: Achieved by 30% of patients (vs. 3% on placebo)
- Trial ID: PubMed 40934115
These results are comparable to what the injectable Wegovy 2.4 mg achieved in the STEP 1 trial (14.9% weight loss at 68 weeks), which is notable because the pill offers a non-injection route with similar efficacy.
OASIS 1 (Higher Dose Study)
This earlier trial tested a 50 mg dose in 612 adults without diabetes over 68 weeks. Weight loss averaged 15.1%, with 34% of participants hitting the 20% threshold. Published in The Lancet in June 2023 (PubMed 37385278). The 50 mg dose was ultimately not the one submitted for approval — Novo Nordisk went with 25 mg, which showed a strong benefit-to-side-effect ratio.
OASIS 2 (East Asian Population)
Tested 50 mg oral semaglutide in 201 East Asian adults with or without type 2 diabetes. Average weight loss of 14.3% vs. 1.3% on placebo at 68 weeks, and 84.3% of participants lost at least 5% of their body weight. Published in JAMA Internal Medicine in April 2024.
Oral vs. Injectable Wegovy: How They Compare
| Factor | Oral Wegovy (Pill) | Injectable Wegovy (Shot) |
|---|---|---|
| How you take it | Daily pill, empty stomach, 30-min fast | Weekly subcutaneous injection |
| Approved dose | 25 mg once daily | 2.4 mg once weekly |
| Average weight loss | ~16.6% (OASIS 4, 64 weeks) | ~14.9% (STEP 1, 68 weeks) |
| Needle required | No | Yes (auto-injector pen) |
| Refrigeration | Not required | Required until first use |
| GI side effects | Higher (74% reported GI events) | Lower (~44% GI events) |
| Excessive belching | ~14% of patients | Near 0% |
| Self-pay cost | $149–$299/month | ~$940–$1,350/month |
| Insurance copay | $0–$25/month | $0–$25/month |
| Travel friendly | Very (no cold chain needed) | Moderate (cold storage initially) |
The practical difference: the pill is easier (see our GLP-1 weight loss timeline for expected results over time), to travel with, requires no needles, and costs substantially less out-of-pocket. The tradeoff is a daily dosing commitment with a strict fasting window, and somewhat higher rates of GI side effects in the first few weeks.
Dosing Schedule
Oral Wegovy uses a gradual dose-escalation schedule to minimize side effects. You'll start low and increase over several months:
| Weeks | Daily Dose | Phase |
|---|---|---|
| Weeks 1–4 | 1.5 mg | Initiation |
| Weeks 5–8 | 4 mg | Escalation |
| Weeks 9–12 | 9 mg | Escalation |
| Week 13+ | 25 mg | Maintenance |
Most people won't see dramatic weight loss during the first month or two — that's expected. The dose-escalation period helps your body adjust and reduces the severity of nausea and other GI side effects. The meaningful weight loss kicks in once you reach the maintenance dose.
Side Effects
The side effect profile is similar to injectable Wegovy, but with some differences worth knowing about.
Most Common (reported by ≥10% of patients in OASIS 4)
- Nausea: The most frequently reported side effect. Tends to be worst during dose escalation and improves as your body adjusts.
- Diarrhea: Usually mild and transient.
- Vomiting: More common during dose-escalation weeks.
- Constipation: Some patients experience this instead of (or alternating with) diarrhea.
- Belching / excessive burping: Reported in about 14% of oral Wegovy users vs. nearly 0% with the injection. This is unique to the pill formulation, likely related to the SNAC absorption process in the stomach.
Overall, 74% of participants in OASIS 4 reported some form of gastrointestinal side effect, compared to 42% on placebo. The vast majority of these were mild to moderate and resolved within weeks. Treatment discontinuation due to side effects was slightly higher with the oral form (roughly 4–8%) compared to the injection (~4%).
Most GI side effects peak during dose escalation and settle within the first month at each new dose level. Eating smaller meals, staying hydrated, and avoiding high-fat foods during these transition periods can help. If nausea is severe, your doctor may extend the time at a lower dose before increasing.
Cost and Insurance Coverage
One of the biggest advantages of oral Wegovy is price. Novo Nordisk launched it with aggressive temporary pricing to drive adoption.
Self-Pay (No Insurance)
- Through August 31, 2026: $149/month for starter doses (1.5 mg and 4 mg)
- After August 2026 (expected): 4 mg = $199/month; 9 mg and 25 mg = $299/month
Compare this to injectable Wegovy at $940–$1,350/month without insurance. For uninsured patients, the pill closes a pricing gap that kept many people off GLP-1 therapy entirely.
Commercial Insurance
Novo Nordisk reports that 90% of commercially insured patients pay $0–$25/month for oral Wegovy. Copay savings cards reduce out-of-pocket costs up to $100/month.
Medicare
This is the big change coming in 2026. Starting July 1, 2026, Medicare Part D will cover oral Wegovy through the Medicare GLP-1 Bridge program at approximately $50/month. This program runs through December 2026, with the BALANCE Model expected to follow in 2027 for longer-term coverage. Medicare Part D also already covers Wegovy when the patient has documented cardiovascular disease.
Medicaid
Coverage varies by state. As of early 2026, 13 states cover GLP-1 medications for weight loss through Medicaid. All 50 state Medicaid programs can access $245/month pricing under a November 2025 agreement with Novo Nordisk, but formulary inclusion is still being rolled out.
Where to Get It
Oral Wegovy launched at U.S. pharmacies on January 5, 2026, and Novo Nordisk has reported it's now broadly available at over 70,000 pharmacy locations.
Retail Pharmacies
CVS, Walgreens, Costco, and most other major chains carry oral Wegovy. Availability can still vary by location and dose strength — call ahead if you want to confirm stock before filling.
Telehealth Programs
Several telehealth platforms prescribe oral Wegovy with online consultations and home delivery:
Ro
Online consultation with licensed providers. Prescribes oral Wegovy with home delivery. Includes ongoing weight management support.
View Program →Hims & Hers
Partnered with Novo Nordisk in early 2026 for FDA-approved Wegovy distribution. Includes telemedicine visits and ongoing support.
View Program →Found
Full weight-care platform offering oral Wegovy prescriptions with health coaching and metabolic testing.
View Program →Calibrate
One-year metabolic health program. Prescribes oral and injectable Wegovy with structured lifestyle support.
View Program →Noom
Clinical program pairing GLP-1 prescriptions (including oral Wegovy) with behavioral coaching and their signature psychology-based approach.
View Program →Direct-to-patient options also include NovoCare Pharmacy (Novo Nordisk's own pharmacy) and most major pharmacy benefit managers (PBMs).
Oral Wegovy vs. Rybelsus: Not the Same Thing
This is a common source of confusion. Both are oral semaglutide tablets made by Novo Nordisk. But they're different products with different approved uses.
| Feature | Oral Wegovy | Rybelsus |
|---|---|---|
| Approved for | Chronic weight management | Type 2 diabetes only |
| Highest dose | 25 mg | 14 mg |
| Available doses | 1.5, 4, 9, 25 mg | 3, 7, 14 mg |
| CV risk indication | Yes | No |
| Same SNAC technology | Yes | Yes |
The weight-loss dose (25 mg) is nearly twice the highest Rybelsus dose (14 mg). Taking extra Rybelsus tablets to reach a higher dose is not a substitute — the formulations have different escalation schedules and the dosing isn't interchangeable. If weight loss is your goal, ask your doctor about oral Wegovy specifically.
What's Coming Next: Competing Oral GLP-1s
Oral Wegovy has a head start, but it won't be alone for long. The oral GLP-1 market is about to get crowded.
Orforglipron (Foundayo) — Eli Lilly
FDA-approved in April 2026, orforglipron is a non-peptide oral GLP-1 receptor agonist. Unlike semaglutide, it doesn't rely on SNAC technology — it's a small molecule that's naturally absorbed. In the ATTAIN-1 trial, patients on the highest dose lost an average of 12.4% body weight at 72 weeks, and about 60% achieved ≥10% weight loss. Early head-to-head comparisons suggest orforglipron may offer competitive results against oral semaglutide, though the two haven't been directly compared at approved doses.
Amycretin — Novo Nordisk
Novo Nordisk's next-generation molecule combines GLP-1 and amylin receptor activity. Both oral and subcutaneous formulations are in development, with Phase 3 trials expected to begin in 2026. Early Phase 2 data showed 13% weight loss in just 12 weeks, suggesting this could be significantly more potent than current options.
VK2735 — Viking Therapeutics
A dual GLP-1/GIP receptor agonist (similar mechanism to tirzepatide) in oral form. Phase 2 results were promising, and Phase 3 planning is underway. Still years from potential approval.
The bottom line: if you've been waiting for a GLP-1 pill, the options are expanding quickly. Oral Wegovy is here now and proven; competitors are arriving or on the horizon.
Frequently Asked Questions
When was oral Wegovy approved?
December 22, 2025. It became broadly available at U.S. pharmacies starting January 5, 2026.
How much weight can you lose on oral Wegovy?
In the OASIS 4 trial, patients lost an average of 16.6% of their body weight over 64 weeks. About 30% of participants achieved 20% or greater weight loss. Individual results vary based on factors like starting weight, diet, exercise, and adherence.
Is oral Wegovy the same as Rybelsus?
No. Both are oral semaglutide, but Rybelsus is approved only for type 2 diabetes at doses up to 14 mg. Oral Wegovy is approved for weight management at doses up to 25 mg. They're different products with different indications, and the doses aren't interchangeable.
Do you have to take oral Wegovy on an empty stomach?
Yes. Take it first thing in the morning with no more than 4 ounces of plain water. Wait at least 30 minutes before eating, drinking, or taking other medications. The SNAC absorption technology requires an empty stomach to work properly.
Does Medicare cover oral Wegovy?
Starting July 1, 2026, Medicare Part D will cover oral Wegovy under the Medicare GLP-1 Bridge program at about $50/month. This runs through December 2026. Medicare Part D also covers Wegovy for patients with documented cardiovascular disease.
Can I switch from injectable Wegovy to the pill?
Yes, but work with your doctor on the transition. The dosing schedules are different (daily pill vs. weekly injection), and you'll likely need to go through a new dose-escalation period. Your doctor can advise on the safest switchover protocol based on your current dose.
What if I miss a dose?
Take the missed dose as soon as you remember, as long as you can still observe the 30-minute fasting window. If it's close to your next scheduled dose, skip the missed one. Do not double up.
Sources
All clinical data and regulatory information on this page has been verified against primary sources:
- Novo Nordisk: FDA Approves Oral Wegovy (Dec 22, 2025 press release)
- OASIS 4 Trial — Oral Semaglutide 25 mg for Obesity (PubMed 40934115)
- OASIS 1 Trial — Oral Semaglutide 50 mg for Obesity, The Lancet (PubMed 37385278)
- SNAC Absorption Mechanism — Nature Communications (2025)
- Novo Nordisk: Oral Wegovy Broadly Available (Jan 2026 press release)
- STAT News: Eli Lilly Obesity Pill Orforglipron (Foundayo) Approved (Apr 2026)
Stay Informed
Get the GLP-1 Insider Brief
Exclusive provider discounts, healthy living guides for your GLP-1 journey, and the latest breakthroughs in peptide science — delivered free.
No spam. Unsubscribe any time.